- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
ERCC5 Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP17894b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP17894b-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
ERCC5 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | P28715 |
| Other Accession | NP_000114.2 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 133108 Da |
ERCC5 Antibody (C-term) - Additional info | |
| Gene ID 2073 | |
| Other Names ERCC5; ERCM2; XPG; XPGC; DNA repair protein complementing XP-G cells; DNA excision repair protein ERCC-5; Xeroderma pigmentosum group G-complementing protein | |
| Target/Specificity This ERCC5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1150-1178 amino acids from the C-terminal region of human ERCC5. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions ERCC5 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
ERCC5 Antibody (C-term) - Protein Information | |
| Name ERCC5 | |
| Synonyms ERCM2, XPG, XPGC | |
| Function Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER). Acts as a cofactor for a DNA glycosylase that removes oxidized pyrimidines from DNA. May also be involved in transcription-coupled repair of this kind of damage, in transcription by RNA polymerase II, and perhaps in other processes too | |
| Cellular Location Nucleus. | |
ERCC5 Antibody (C-term) - Related products
ERCC5 Antibody (C-term) - Application data
-
ERCC5 Antibody (C-term) (Cat. #AP17894b) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the ERCC5 antibody detected the ERCC5 protein (arrow).
ERCC5 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G) is involved in excision repair of UV-induced DNA damage. Mutations cause Cockayne syndrome, which is characterized by severe growth defects, mental retardation, and cachexia. Multiple alternatively spliced transcript variants encoding distinct isoforms have been described, but the biological validity of all variants has not been determined. [provided by RefSeq].
REFERENCES
Figl, A., et al. Mutat. Res. 702(1):8-16(2010) Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press : Briggs, F.B., et al. Am. J. Epidemiol. 172(2):217-224(2010) Monsees, G.M., et al. Breast Cancer Res. Treat. (2010) In press : Canbay, E., et al. Anticancer Res. 30(4):1359-1364(2010)
